Page 80 - Haematologica August 2018

G.J. Roboz et al. References
1. Institute NC. Cancer Stat Facts: Acute Myeloid Leukemia (AML). 2014. Available from: http://seer.cancer.gov/statfacts/html/ amyl.html
2. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556-561.
3. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107(16):7473-7478.
4. Bhatnagar B, Duong VH, Gourdin TS, et al. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Leuk Lymphoma. 2014;55 (7):1533-1537.
5. Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diag- nosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013;54(9):2003-2007.
6. Roboz GJ, Guzman M. Acute myeloid leukemia stem cells: seek and destroy. Expert Rev Hematol. 2009;2(6):663-672.
7. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol.
2011;29(5):591-599.
8. Sugiyama T, Kohara H, Noda M, Nagasawa
T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell nich- es. Immunity. 2006;25(6):977-988.
9. Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmen- tal interactions in leukemia: mechanisms and approaches. Drug Resist Updat. 2009;12(4-5):103-113.
10. Cooper TM, Sison EAR, Baker SD, et al. A phase 1 study of the CXCR4 antagonist pler- ixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10- 03). Pediatr Blood Cancer. 2017;64(8).
11. Martinez-Cuadron D, Boluda B, Martinez P, et al. A phase I-II study of plerixafor in com- bination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regi- men) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. Ann Hematol. 2018;97(5):763-772.
12. Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood.
2012;119(17):3917-3924.
13. Vardiman JW, Thiele J, Arber DA, et al. The
2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
14. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommenda- tions from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
15. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21 (24):4642-4649.
16. van Rhenen A, Moshaver B, Kelder A, et al. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distin- guish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia. 2007;21(8):1700-1707.
17. Welch JS, Petti AA, Miller CA, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016;375(21):2023-2036.
1316
haematologica | 2018; 103(8)